This opportunity is no longer accepting applications.
grant PAR-22-185

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

This grant offers researchers the opportunity to request support for preclinical services to help develop products aimed at advancing promising treatments for HIV and related co-infections like Hepatitis B, Hepatitis C, and Tuberculosis. It is available to both academic and private institutions.

The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatiti…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute of Allergy and Infectious Diseases
Program: SBIR

Dates

Opportunity Released: May 27, 2022
Open for Submission: May 27, 2022
Submission Deadline: January 17, 2025
Application Window Closes: January 17, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.